# Durvalumab (Imfinzi)

Source: https://ourhealthnetwork.com/drugs/durvalumab
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Durvalumab?

Durvalumab (brand name: Imfinzi) is a programmed death ligand-1 blocker. It is prescribed to treat carcinoma, transitional cell.

## Brand names

Imfinzi

## Indications

Durvalumab is prescribed for the treatment of carcinoma and transitional cell.

## Conditions treated

- [Carcinoma](https://ourhealthnetwork.com/conditions/carcinoma)
- [Transitional Cell](https://ourhealthnetwork.com/conditions/transitional-cell)

## Mechanism of action

Expression of programmed cell death ligand-1 (PD-L1) can be induced by inflammatory signals (e.g., IFN-gamma) and can be expressed on both tumor cells and tumor-associated immune cells in the tumor microenvironment. PD-L1 blocks T-cell function and activation through interaction with PD-1 and CD80 (B7.1).

## Drug classification

- Established Pharmacologic Class: Programmed Death Ligand-1 Blocker [EPC]
- Mechanism of Action class: Programmed Death Ligand-1 Antagonists [MoA]
- Route of administration: INTRAVENOUS

## Common side effects

decreased calcium, decreased hemoglobin, decreased neutrophils, decreased platelets, decreased sodium, fatigue, increased alt, increased blood creatinine

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)